Skip to content

MRI-Eye Tracking Pairing, a Tool for Assessing Social Cognition in Children With ASD

MRI-Eye Tracking Pairing, a Tool for Assessing Social Cognition in Children With ASD

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05194254
Acronym
IRM-ET
Enrollment
68
Registered
2022-01-18
Start date
2022-01-04
Completion date
2025-06-30
Last updated
2025-05-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ASD, Eye Tracking, Functional Magnetic Resonance Imaging, Joint Attention, Social Cognition

Keywords

ASD, Functional magnetic resonance imaging, Eye Tracking, social cognition, joint attention

Brief summary

Most studies use static visual percepts that are less representative of joint attention versus an ecological environment. This has the consequence of decreasing the perception of an interaction with a social partner, which is an essential step in achieving joint attention. The originality of this study is to improve the design of visual percepts (in the form of video) in order to mimic an ecological environment as much as possible by using MRI-ET coupling. The second originality of this study is the longitudinal exploration of the neurodevelopment of social cognition in autistic children. Studies by the Redcay and Oberwelland teams observe different activations at different ages. The hypothesis is that the perception of joint attention varies over time in people with ASD. To date, there are no studies to determine the influence of childhood neurodevelopment in autistic people on the perception of joint attention. It would be unprecedented to use the MRI-ET pairing as a tool for assessing social cognition as a function of the development of children with ASD.

Interventions

OTHERMRI-ET

coupled fMRI and Eye Tracking tools

Sponsors

Centre Hospitalier Universitaire, Amiens
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
10 Years to 20 Years
Healthy volunteers
Yes

Inclusion criteria

For the group of people with Autism Spectrum Disorders (experimental group): * Age between 10 to 20 years old * Diagnosis of ASD (CARS) ≥ 30 performed at inclusion * IQ test evaluation (regardless of the result) performed by a trained psychologist * Obtaining informed oral and written consent after appropriate information * Obtaining informed oral and written consent from the legal guardian after information * Be affiliated with social security * No contraindication to magnetic resonance imaging For the TD (Typical Development) group of people (control group): * Age between 10 to 20 years old * Diagnosis of ASD (CARS) \<30 performed at inclusion * IQ test evaluation (regardless of the result) performed by a trained psychologist * Obtaining informed oral and written consent after appropriate information * Obtaining informed oral and written consent from the legal guardian after information * Be affiliated with social security * No contraindication to magnetic resonance imaging

Exclusion criteria

For all groups: * Age outside the range 10 to 20 years * Person with a contraindication to MRI (including claustrophobia, pace maker, neurosurgical clips, vascular clips, heart valves, ventriculoperitoneal valves, cochlear implant, neurostimulator, intraocular metal shards, joint prosthesis, etc.) * Person suffering from major obesity (\> 140 kg) not allowing him to enter the tunnel of the MRI machine (diameter \<70cm) * Pregnant or breastfeeding woman * Person under guardianship or guardianship or deprived of liberty by a judicial or administrative decision For TD people (control group): * Person with psychiatric disorders such as attention disorder with or without hyperactivity, depression, bipolar disorder and schizophrenia. * Person with a neurological history such as epilepsy and / or neurovascular accident.

Design outcomes

Primary

MeasureTime frameDescription
difference of mapping IRM-ET results between both patient groupsone dayboth patient groups are : the group of people with Autism Spectrum Disorders and Typical Development group of people

Countries

France

Contacts

Primary ContactJean-Marc Constans, Pr
constans.jean-marc@chu-amiens.fr03 22 08 75 15

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026